Legend Biotech names Novartis veteran Ingrid Zhang as permanent CEO
The CAR-T cell therapy maker has filled its top job with a 15-year Novartis executive as it pushes to expand commercial reach.
Legend Biotech has named Ingrid Zhang, a 15-year Novartis veteran, as its permanent CEO. Both Fierce Pharma and Fierce Biotech report the appointment, describing the CAR-T specialist as looking toward its next phase of growth.
Zhang's background is in commercial operations, which aligns with the company's push to boost commercial potential. The two reports agree on her credentials and the strategic intent behind the hire.
The reports differ slightly in context. Fierce Biotech notes that Zhang replaces Ying Huang, who left suddenly in July; Fierce Pharma's piece does not mention Huang's departure. That context matters for understanding the leadership transition.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.